NeuroBo Pharmaceuticals I... (NRBO)
NASDAQ: NRBO
· Real-Time Price · USD
2.36
null (null%)
At close: Nov 27, 2024, 10:00 PM
NeuroBo Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | 20K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 10K | n/a | 6K | 4K | 4K | 1K | n/a | 1K | 1K | 2K | 7K | 12K | 36K | 12K | n/a | n/a |
Gross Profit | n/a | n/a | 10K | n/a | -6K | -4K | 2K | -1K | n/a | -1K | -1K | -2K | -7K | -12K | -36K | -12K | -19K | -17K |
Operating Income | -4.3M | -3.89M | -5.58M | -6.26M | -10.08M | -6.88M | -5.67M | -3.89M | -3.81M | -2.52M | -2.22M | -3.1M | -3.22M | -2.88M | -4.58M | -3.46M | -3.93M | -3.33M |
Interest Income | 146K | 128K | 209K | 310K | 164K | 237K | 299K | 162K | n/a | n/a | 2.19K | n/a | n/a | n/a | 14K | 3K | 5K | 6K |
Pretax Income | -4M | -3.67M | -5.17M | -5.65M | -10.05M | -6.71M | -5.31M | -3.82M | -734K | -2.6M | -4.68M | -3.11M | -3.3M | -2.88M | -4.58M | -3.46M | -3.92M | -3.32M |
Net Income | -4M | -3.67M | -5.17M | -5.65M | -10.05M | -6.71M | -5.31M | -3.82M | -734K | -2.6M | 994K | -3.12M | -3.3M | -2.88M | -4.58M | -3.46M | -3.92M | -3.32M |
Selling & General & Admin | 1.98M | 1.56M | 1.54M | 1.74M | 2M | 1.97M | 1.8M | 1.6M | 1.44M | 1.88M | 1.92M | 2.53M | 2.24M | 1.96M | 2.58M | 2.07M | 1.91M | 2.19M |
Research & Development | 2.32M | 2.33M | 4.06M | 4.52M | 8.07M | 4.9M | 3.86M | 2.29M | 2.36M | 637K | 305K | 571K | 982K | 920K | 2M | 1.39M | 2.01M | 1.14M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 4K | n/a | n/a | n/a | 10K | -9K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 4.3M | 3.89M | 5.59M | 6.26M | 10.08M | 6.88M | 5.66M | 3.89M | 3.81M | 2.52M | 2.22M | 3.1M | 3.22M | 2.88M | 4.58M | 3.46M | 3.93M | 3.33M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 84K | 2.19M | 9K | n/a | n/a | 10.71M | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | 10K | n/a | -6K | -4K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | n/a | 5.61M | 6.26M | 10.08M | 6.88M | 5.67M | 3.89M | 3.81M | 2.52M | 2.22M | 3.1M | 3.22M | 2.88M | 4.58M | 3.46M | 3.93M | 3.33M |
Income Tax Expense | n/a | n/a | 39.28K | n/a | n/a | -39.28K | n/a | -1K | n/a | n/a | -5.67M | 9K | -2K | n/a | n/a | n/a | -7K | -5K |
Shares Outstanding (Basic) | 15.29M | 10.26M | 77.57M | 10.21M | 5.43M | 5.09M | 5.08M | 5.08M | 5.06M | 5.06M | 3.18M | 888.69K | 888.69K | 888.69K | 742.85K | 742.81K | 733.34K | 720.52K |
Shares Outstanding (Diluted) | 15.29M | 10.26M | 77.57M | 10.21M | 5.43M | 5.09M | 5.08M | 5.08M | 5.06M | 5.06M | 3.18M | 888.69K | 888.69K | 888.73K | 742.85K | 742.81K | 733.34K | 90.06K |
EPS (Basic) | -0.26 | -0.36 | 0.16 | -0.55 | -1.85 | -1.32 | -1.05 | -0.75 | -0.15 | -0.51 | 0.31 | -3.51 | -3.72 | -3.24 | -6.16 | -4.66 | -5.35 | -36 |
EPS (Diluted) | -0.26 | -0.36 | 0.16 | -0.55 | -1.85 | -1.32 | -1.05 | -0.75 | -0.15 | -0.51 | 0.31 | -3.51 | -3.72 | -3.23 | -6.16 | -4.66 | -5.35 | -36 |
EBITDA | -4.3M | -3.89M | -5.15M | -6.25M | -10.08M | -6.88M | -2.25M | -3.89M | -3.81M | -2.52M | -2.58M | -3.1M | -3.21M | -2.86M | -4.57M | -3.45M | -3.91M | -3.32M |
EBIT | n/a | n/a | 23.22M | -6.26M | -10.08M | -6.88M | -2.25M | -3.89M | -3.81M | -2.52M | -2.48M | -3.1M | -3.22M | -2.88M | -4.58M | -3.46M | -3.93M | -3.33M |
Depreciation & Amortization | n/a | n/a | -15K | 5K | 6K | 4K | 4K | 1K | -3.07M | 1K | 1K | 2K | 7K | 12K | 12K | 12K | 12K | 12K |